Literature DB >> 20806340

Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.

Amosy E M'Koma1, Erin H Seeley, Mary K Washington, David A Schwartz, Roberta L Muldoon, Alan J Herline, Paul E Wise, Richard M Caprioli.   

Abstract

BACKGROUND: Differentiating ulcerative colitis (UC) from Crohn's colitis (CC) can be difficult and may lead to inaccurate diagnoses in up to 30% of inflammatory bowel disease (IBD) patients. Much of the diagnostic uncertainty arises from the overlap of clinical and histologic features. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) permits a histology-directed cellular protein analysis of tissues. As a pilot study, we evaluated the ability of histology-directed MALDI-MS to determine the proteomic patterns for potential differences between CC and UC specimens.
METHODS: Mucosal and submucosal layers of CC and UC colon resection samples were analyzed after histologic assessment. To determine whether MALDI-MS would distinguish inflammation, the uninflamed (n = 21) versus inflamed submucosa (n = 22) were compared in UC and the uninflamed (n = 17) versus inflamed submucosa (n = 20) in CC. To determine whether there were proteomic differences between the colitides, the uninflamed UC submucosa (n = 21) was compared versus the uninflamed CC submucosa (n = 17), the inflamed UC submucosa (n = 22) was compared versus the inflamed CC submucosa (n = 20), and inflamed UC mucosa versus inflamed CC mucosa. Pairwise statistics comparisons of the subsets were performed.
RESULTS: Pairwise comparative analyses of the clinical groups allowed identifying subsets of features important for classification. Comparison of inflamed versus uninflamed CC submucosa showed two significant peaks: m/z 6445 (P = 0.0003) and 12692 (P = 0.003). In the case of inflamed versus uninflamed UC submucosa, several significant differentiating peaks were found, but classification was worse. Comparisons of the proteomic spectra of inflamed submucosa between UC and CC identified two discrete significant peaks: m/z 8773 (P = 0.006) and 9245 (P = 0.0009). Comparisons of the proteomic spectra of uninflamed submucosa between UC and CC identified three discrete significant peaks: m/z 2778 (P = 0.005), 9232 (P = 0.005), and 9519 (P = 0.005). No significantly different features were found between UC and CC inflamed mucosa.
CONCLUSIONS: MALDI-MS was able to distinguish CC and UC specimens while profiling the colonic submucosa. Further analyses and protein identification of the differential protein peaks may aid in accurately diagnosing IBD and developing appropriate personalized therapies.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806340      PMCID: PMC2997147          DOI: 10.1002/ibd.21442

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  35 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  Inflammatory bowel disease and environmental influences.

Authors:  Aruna Krishnan; Joshua R Korzenik
Journal:  Gastroenterol Clin North Am       Date:  2002-03       Impact factor: 3.806

3.  Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease.

Authors:  Howard A Kader; Velizar T Tchernev; Ebenezer Satyaraj; Serguei Lejnine; Gregory Kotler; Stephen F Kingsmore; Dhavalkumar D Patel
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

4.  Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.

Authors:  Marie-Alice Meuwis; Marianne Fillet; Pierre Geurts; Dominique de Seny; Laurence Lutteri; Jean-Paul Chapelle; Vincent Bours; Louis Wehenkel; Jacques Belaiche; Michel Malaise; Edouard Louis; Marie-Paule Merville
Journal:  Biochem Pharmacol       Date:  2006-12-20       Impact factor: 5.858

5.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

Review 6.  Crohn's disease of the ileal pouch: reality, diagnosis, and management.

Authors:  Bo Shen
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

Review 7.  Serologic markers in inflammatory bowel disease.

Authors:  Xavier Bossuyt
Journal:  Clin Chem       Date:  2005-12-08       Impact factor: 8.327

8.  HIGH DIMENSIONAL VARIABLE SELECTION.

Authors:  Larry Wasserman; Kathryn Roeder
Journal:  Ann Stat       Date:  2009-01-01       Impact factor: 4.028

9.  Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.

Authors:  Marie-Alice Meuwis; Marianne Fillet; Laurence Lutteri; Raphaël Marée; Pierre Geurts; Dominique de Seny; Michel Malaise; Jean-Paul Chapelle; Louis Wehenkel; Jacques Belaiche; Marie-Paule Merville; Edouard Louis
Journal:  Clin Biochem       Date:  2008-05-06       Impact factor: 3.281

10.  Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.

Authors:  Joshua A Bauer; A Bapsi Chakravarthy; Jennifer M Rosenbluth; Deming Mi; Erin H Seeley; Nara De Matos Granja-Ingram; Maria G Olivares; Mark C Kelley; Ingrid A Mayer; Ingrid M Meszoely; Julie A Means-Powell; Kimberly N Johnson; Chiaojung Jillian Tsai; Gregory D Ayers; Melinda E Sanders; Robert J Schneider; Silvia C Formenti; Richard M Caprioli; Jennifer A Pietenpol
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

View more
  34 in total

1.  Comprehensive identification of proteins from MALDI imaging.

Authors:  Stefan K Maier; Hannes Hahne; Amin Moghaddas Gholami; Benjamin Balluff; Stephan Meding; Cédrik Schoene; Axel K Walch; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2013-06-19       Impact factor: 5.911

Review 2.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 3.  Imaging of intact tissue sections: moving beyond the microscope.

Authors:  Erin H Seeley; Kristina Schwamborn; Richard M Caprioli
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

Review 4.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

Review 5.  MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice.

Authors:  Michaela Aichler; Axel Walch
Journal:  Lab Invest       Date:  2015-01-26       Impact factor: 5.662

Review 6.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

Review 7.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.

Authors:  Heitor S P de Souza; Claudio Fiocchi; Dimitrios Iliopoulos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

Review 8.  Systems medicine: evolution of systems biology from bench to bedside.

Authors:  Rui-Sheng Wang; Bradley A Maron; Joseph Loscalzo
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2015-04-17

9.  Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.

Authors:  Erin H Seeley; Mary K Washington; Richard M Caprioli; Amosy E M'Koma
Journal:  Proteomics Clin Appl       Date:  2013-05-08       Impact factor: 3.494

Review 10.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.